BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32638647)

  • 1. Alternative management of Covid-19 infection.
    Atrah HI
    Scott Med J; 2020 Aug; 65(3):72-75. PubMed ID: 32638647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposed use of thalidomide for the cytokine storm of COVID-19.
    Goihman-Yahr M
    Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614
    [No Abstract]   [Full Text] [Related]  

  • 3. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
    Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
    [No Abstract]   [Full Text] [Related]  

  • 6. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
    ; Jacob S; Muppidi S; Guidon A; Guptill J; Hehir M; Howard JF; Illa I; Mantegazza R; Murai H; Utsugisawa K; Vissing J; Wiendl H; Nowak RJ
    J Neurol Sci; 2020 May; 412():116803. PubMed ID: 32247193
    [No Abstract]   [Full Text] [Related]  

  • 7. Tocilizumab administration in a refractory case of COVID-19.
    Dastan F; Nadji SA; Saffaei A; Tabarsi P
    Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
    [No Abstract]   [Full Text] [Related]  

  • 8. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.
    Liu X; Cao W; Li T
    Front Immunol; 2020; 11():1660. PubMed ID: 32760407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
    Nguyen AA; Habiballah SB; Platt CD; Geha RS; Chou JS; McDonald DR
    Clin Immunol; 2020 Jul; 216():108459. PubMed ID: 32418917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapsone and doxycycline could be potential treatment modalities for COVID-19.
    Farouk A; Salman S
    Med Hypotheses; 2020 Jul; 140():109768. PubMed ID: 32339778
    [No Abstract]   [Full Text] [Related]  

  • 11. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report.
    Daneshpazhooh M; Soori T; Isazade A; Noormohammadpour P
    J Dermatolog Treat; 2020 Aug; 31(5):446-447. PubMed ID: 32363963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
    Abdulrab S; Al-Maweri S; Halboub E
    Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment considerations for patients with pemphigus during the COVID-19 pandemic.
    Shakshouk H; Daneshpazhooh M; Murrell DF; Lehman JS
    J Am Acad Dermatol; 2020 Jun; 82(6):e235-e236. PubMed ID: 32283243
    [No Abstract]   [Full Text] [Related]  

  • 17. May IL-17 have a role in COVID-19 infection?
    Megna M; Napolitano M; Fabbrocini G
    Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.
    Balasubramanian S; Nagendran TM; Ramachandran B; Ramanan AV
    Indian Pediatr; 2020 Jul; 57(7):681-683. PubMed ID: 32393681
    [No Abstract]   [Full Text] [Related]  

  • 19. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.
    Ye Q; Wang B; Mao J
    J Infect; 2020 Jun; 80(6):607-613. PubMed ID: 32283152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.